Chart 1_S&P500 returns around recession 23 May 22

Markets – possible technical rebound in the near term but likely short lived (26 May 2022)

Dear all I have been extremely busy with work, hence the dearth of articles on my blog. Dow has closed lower for the eighth consecutive week. This marks the longest period of consecutive weekly losses since 1923! S&P500 has registered a seventh week of losses, its longest weekly losing streak since March 2001. Are the markets going to drop into an abyss? Or has the bottom been reached? Before we delve into this, let’s recap on my earlier market outlook article dated 4 Apr 22 (click HERE). Previously, I wrote that I am more inclined towards the bearish / prudent […]

Fig 1_SMG Group overview Aug 2021

Sing Medical – Trades at a 13-month low price despite posting record 1HFY21 results (3 Feb 22)

Dear all On 29 Dec 2020, I have published a write-up on Sing Medical (“SMG”) where I outlined that the risk reward on SMG seems favourable at $0.315, given a potential share transaction scenario (click HERE). Since 29 Dec, SMG rose approximately 32% to trade $0.415 – 0.420 on several occasions in Feb 2021. Subsequently, it dropped sharply in Apr 2021 when it announced that the potential share transaction has lapsed. Fast forward to 31 Jan 2022 and SMG closed at a 13-month low at $0.290. This is notwithstanding its sterling record 1HFY21 results announced in Aug last year where […]

Table 2_Top ten stocks sorted by total potential return 31 Dec 21

Will Singapore stocks outperform U.S. stocks in 2022? (5 Jan 2022)

Dear all With reference to my market outlook published on 7 Nov (see HERE) citing our Singapore market may face near term profit taking, STI dropped 201 points, or 6.6% from 3,242 on 5 Nov to close at 3,041 on 30 Nov. As we start 2022, various investment banks and research houses have put forth their views on how the various markets will perform. In this write-up, I will share how the markets have performed in 2021 and my market outlook in 2022.   How did the markets perform in 2021? Based on Table 1 below, it is evident that […]

China Aoyuan Analyst 11 Jun 21

China Aoyuan – a potential value play? (15 Jun 21)

Dear all Against the backdrop of rising inflation, some market strategists have recommended “additional urgency” to rotate from technology plays to “old economy value stocks” to hedge against potential inflation pressures (as they believe such inflation pressures are not transitory). A stock that may tick all the right boxes may be China Aoyuan (“Aoyuan”) (3883.HK). It belongs to the old economy stocks (i.e. property sector which may be a hedge against inflation) and seems to be a value play, given that it trades at HKD7.01 on 15 Jun 21.   Who is Aoyuan? Quoting from a report by DBS Research […]

Analyst 11 Sep 20

Riverstone – Is the recent 32% decline justified? (12 Sep 2020)

Riverstone recently caught my attention. It has tumbled approximately 32% from an intraday high of $4.90 on 7 Aug 2020 to close $3.33 on 11 Sep 2020. One client even thought that Riverstone has already undergone a bonus issue! The recent weakness is likely attributed to its co-founder selling 15.5m shares at $3.95 (Bloomberg cites a 90-day lockup on seller); the possibility of a vaccine resulting in demand for gloves and consequently their average selling price (“ASP”) falling off the cliff and some Malaysia investors selling shares to raise cash, as their moratorium on loan repayment ends (click HERE for […]

Starburst chart as of 23 Aug 20

Starburst – building order books; bright outlook (24 Aug 2020)

In May 2019, I met Starburst’s Managing and Executive Director Mr Yap Tin Foo. Since Mar 2020, Starburst has been on a roll in winning contracts and I believe it is an opportune time to meet Mr Yap again. Despite Mr Yap’s busy schedule, he agrees to meet me on 1-1 basis to share his company’s business operations and prospects. Below are some of my takeaways from my discussion with him and from its recent results briefing.   Company description Quoting from Starburst’s press release, it is an engineering specialist in a niche industry, and designs, fabricates, installs and maintains […]

Sing Medical – Chart seems to be strengthening (13 Feb 2019)

This week, Sing Medical’s (“SMG”) caught my attention. At the time of writing this write-up, SMG is trading +0.005 to $0.430. Day range 0.425 – 0.430.   Some interesting observations on SMG a) Chart seems to be strengthening Based on Chart 1 below, SMG seems to have breached the near term downtrend line established since Mar 2018. Today is T+7 of the sharp upmove dated 31 Jan 2019 thus, I guess those contra players (who plan to contra and not hold the stock) have already exited. Indicators such as OBV, RSI and MACD are strengthening. ADX last trades 34.5 on […]

Sing medical analyst target price 2 Oct 18

Sing Medical trades near one year low despite a 70% jump in 1HFY18 net profit! (3 Oct 2018)

This week, Sing Medical (“SMG”) caught my attention. SMG has dropped 39% from $0.725 on 18 Jul 2017 to trade $0.440 on 3 Oct 2018. My personal guess is part of the fall may be attributable to a) Lower, or no earnings growth for some of the healthcare players in FY18F. However, this is likely not the case for SMG, as analysts believe SMG is on track for a minimum 40% growth in FY18F net profit. It is noteworthy that SMG already posted a 70% jump in 1HFY18 net profit; b) Reduction in the general PE valuations ascribed to the […]